Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYSA1801 + capecitabine versus oxaliplatin + capecitabine as first-line treatment for CLDN18.2-positive, PD-L1 CPS <5 unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma
CTR20244240Phase 3Active
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Dec 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of SYSA1801 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by CSPC Megalith Biopharmaceutical Co., Ltd.. Started Dec 2024; status: active.
02
Drugs
SYSA1801
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20244240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244240.